Affordable Access

A robust prognostic gene expression signature for early stage lung adenocarcinoma

Authors
Publication Date
Source
Online Research Database In Technology
Keywords
  • Early Stage Cancer
  • Gene Expression
  • Lung Adenocarcinoma
  • Prognostic Biomarker
External links

Abstract

Stage I lung adenocarcinoma is usually not treated with adjuvant chemotherapy; however, around half of these patients do not survive 5 years. Therefore, a reliable prognostic biomarker for early stage patients would be critical to identify those most likely to benefit from early additional treatments. Several studies have searched for gene expression prognostic biomarkers for lung adenocarcinoma, but these have not yielded a widely accepted prognosticator. We analyzed gene expression from seven published lung adenocarcinoma cohorts for which we included only stage I and II patients who were not given adjuvant therapy. Seven genes consistently obtained statistical significance in Cox regression for overall survival. The combined signature has a weighted mean hazard ratio of 3.2 in all cohorts and 3.0 (C.I. 1.3-7.4, p

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments